Even though the clinical relevance with the aforementioned cardiovascular threat factor alterations by tirzepatide is going to be assessed while in the prepared cardiovascular end result study SURPASS-CVOT ( "sort":"scientific-trial","attrs": "text":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Investigatio